Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

2013 trends

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Lucid Group Communications Limited

- PMLiVE

Quintiles founder Dr Dennis Gillings to retire as chairman

He will be replacedin that role by Jack Greenberg

- PMLiVE

Meda collaborates on asthma comic book

Launches new Explain Asthma volume at ACAAI annual meeting

- PMLiVE

FDA accepts Sandoz filing for biosimilar Neulasta

Theversion of Amgen's blockbuster will have a 10-month review period

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

- PMLiVE

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Lucid Group Communications Limited

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

Takeda UK adds to its senior leadership team

Simon Meadowcroft and Pauline Bromley join the firm 

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

AZ sets price of new lung cancer drug Tagrisso

Price tag of $150,000 per year given

- PMLiVE

Crescendo Biologics appoints Dr Kevin Johnson as chairman

Brings Cambridge, UKfirm experience from Pangenetics

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links